Cargando…

Adverse events following remdesivir administration in moderately ill COVID-19 patients - A retrospective analysis

INTRODUCTION: Remdesivir, an antiviral drug, received an emergency use authorization for treating coronavirus disease 2019 (COVID-19) patients. Though many studies have reported the safety aspects of this antiviral agent, most of them were observed in severely ill COVID-19 patients, making very less...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gandham, Ravi, Eerike, Madhavi, Raj, Gerard M., Bisoi, Debasis, Priyadarshini, Rekha, Agarwal, Neeraj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648220/ https://www.ncbi.nlm.nih.gov/pubmed/36387660 http://dx.doi.org/10.4103/jfmpc.jfmpc_2468_21

Ejemplares similares

Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review
por: Mali, Kalpana Ramanna, et al.
Publicado: (2022)

Anti-spike Antibody Status in Pre-vaccinated Healthy Participants and Rheumatoid Arthritis Patients During the Third Wave of COVID-19
por: Eerike, Madhavi, et al.
Publicado: (2023)

Effect of Remdesivir Administration on Occurrence of Major Adverse Cardiac Events in Critically Ill COVID-19 Pneumonia: A Retrospective Observational Study
por: Panda, Rajesh, et al.
Publicado: (2022)

Cardiac Adverse Events With Remdesivir in COVID-19 Infection
por: Gupta, Anupam K, et al.
Publicado: (2020)

Remdesivir vs tocilizumab in COVID-19: adverse event profiles
Publicado: (2021)

Remdesivir Treatment in Moderately Ill COVID-19 Patients: A Retrospective Single Center Study
por: Terkes, Vedrana, et al.
Publicado: (2022)

CLINICAL EFFECTIVENESS AND ADVERSE EVENTS OF ADJUNCTIVE REMDESIVIR ADMINISTRATION VS STANDARD OF CARE IN ADULTS WITH SEVERE AND CRITICAL COVID-19
por: Viray, D.D., et al.
Publicado: (2023)

Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System
por: Rafaniello, Concetta, et al.
Publicado: (2021)

Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System
por: Li, Xiaotong, et al.
Publicado: (2023)

Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study
por: Miyazaki, Motoyasu, et al.
Publicado: (2022)

Postmarketing pharmacovigilance: Remdesivir and cardiovascular events
por: Sullivan, John T.
Publicado: (2022)

Pulmonary administration of remdesivir in the treatment of COVID-19
por: Rasmussen, Henrik Berg, et al.
Publicado: (2020)

Remdesivir treatment for patients with moderate to severe COVID-19
por: HASANOĞLU, İmran, et al.
Publicado: (2022)

Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies
por: Guha, Avirup, et al.
Publicado: (2022)

561. Safety of Remdesivir vs Standard Care in Patients with Moderate Covid-19
por: Criner, Gerard J, et al.
Publicado: (2020)

Prevention of adverse events in the administration of drugs
por: Diano, G, et al.
Publicado: (2010)

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports
por: Kato, Yamato, et al.
Publicado: (2015)

Remdesivir in moderate to severe COVID-19: A matter of time?
por: Bonazzetti, Cecilia, et al.
Publicado: (2021)

Use of canakinumab and remdesivir in moderate-severe COVID-19 patients: A retrospective analysis
por: Mastroianni, Antonio, et al.
Publicado: (2023)

Adverse Drug Events Associated With Remdesivir in Real-World Hospitalized Patients With COVID-19, Including Vulnerable Populations: A Retrospective Multicenter Study
por: Kang, Hyein, et al.
Publicado: (2023)

EPH43 Potential Association of Remdesivir and Hyperkalemia: A Disproportionality Analysis in USFDA Adverse Event Reporting System Database
por: Das, A., et al.
Publicado: (2023)

72. Remdesivir vs Standard Care in Patients with Moderate covid-19
por: Marty, Francisco M, et al.
Publicado: (2020)

Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis
por: Cherian, Jerin Jose, et al.
Publicado: (2022)

Neurological adverse events following regional anesthesia administration
por: Kent, Christopher D, et al.
Publicado: (2010)

271 Evaluation of Adverse Events Associated to Administration of Omalizumab
por: Gomez, R. Maximiliano, et al.
Publicado: (2012)

Reporting adverse drug events to the Therapeutic Goods Administration
por: Martin, Jennifer H, et al.
Publicado: (2021)

541. The Effect of Early Remdesivir Administration in COVID-19 Disease Progression
por: Platzer, Moritz, et al.
Publicado: (2023)

Nephroprotective effects of ethanolic root extract of Azima tetracantha lam in adenine-induced chronic kidney failure in Wistar rats
por: Arunachalam, Ruckmani, et al.
Publicado: (2021)

Remdesivir
por: Bakheit, Ahmed H., et al.
Publicado: (2023)

A retrospective study of adverse drug events in anticoagulant administration with relevance to COVID-19()
por: Patel, Purva, et al.
Publicado: (2023)

Evaluation of In vivo Antimalarial Property of Nyctanthes arbor-tristis (Night Jasmine) Leaves
por: Das, Lopamudra, et al.
Publicado: (2021)

Remdesivir in pregnant women with moderate to severe coronavirus disease 2019 (COVID-19): a retrospective cohort study
por: Arbabzadeh, Taraneh, et al.
Publicado: (2023)

Automatically Recognizing Medication and Adverse Event Information From Food and Drug Administration’s Adverse Event Reporting System Narratives
por: Polepalli Ramesh, Balaji, et al.
Publicado: (2014)

META-INSTI: metabolic adverse events following integrase strand transfer inhibitor administration in spontaneous adverse event reports
por: Murray, Milena M, et al.
Publicado: (2023)

The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis
por: Peyko, Vincent, et al.
Publicado: (2020)

Genetic polymorphisms of multidrug and toxin extrusion proteins (MATE1 and MATE2) in South Indian population
por: Raj, Gerard Marshall, et al.
Publicado: (2017)

Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration
por: Wang, Yu, et al.
Publicado: (2020)

Retrospective analysis of dermatologic adverse events associated with hydroxychloroquine reported to the US Food and Drug Administration
por: Lipner, Shari R., et al.
Publicado: (2020)

Remdesivir in Breastfeeding
por: Sadati, Elham, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j93dv2ndbersnukarpd84ajj4u